NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report published on Thursday. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NURO opened at $4.51 on Thursday. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73. The stock’s 50-day moving average is $4.30 and its two-hundred day moving average is $4.12. The stock has a market cap of $9.26 million, a PE ratio of -0.98 and a beta of 2.15.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC bought a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned approximately 0.57% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is owned by institutional investors and hedge funds.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.